XL PROTEIN GMBH has a total of 31 patent applications. It increased the IP activity by 200.0%. Its first patent ever was published in 2008. It filed its patents most often in China, EPO (European Patent Office) and Republic of Korea. Its main competitors in its focus markets biotechnology, pharmaceuticals and foods and drinks are GENEXINE CO LTD, PHARM CJSC CLOSED JOINT STOCK COMPANY R and HUMAN GENOME SCIENCES.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 5 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | Republic of Korea | 3 | |
#4 | Mexico | 3 | |
#5 | United States | 3 | |
#6 | WIPO (World Intellectual Property Organization) | 3 | |
#7 | Canada | 2 | |
#8 | Singapore | 2 | |
#9 | Australia | 1 | |
#10 | EAPO (Eurasian Patent Organization) | 1 | |
#11 | Hungary | 1 | |
#12 | Japan | 1 | |
#13 | New Zealand | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Therapeutic chemical compounds | |
#5 | Enzymes | |
#6 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Binder Uli | 22 |
#2 | Skerra Arne | 20 |
#3 | Schlapschy Martin | 15 |
#4 | Friedrich Lars | 8 |
#5 | Achatz Stefan | 6 |
#6 | O'Donnell Anne | 4 |
#7 | Uli Binder | 2 |
#8 | Arne Skerra | 2 |
#9 | Theobald Ina | 2 |
#10 | Skerra Ame | 1 |
Publication | Filing date | Title |
---|---|---|
EP3641827A1 | Conjugates of protein drugs and p/a peptides | |
US2018371446A1 | Modified L-asparaginase | |
EP3418383A1 | Modified l-asparaginase | |
MX2018007680A | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences. | |
AU2014203517A1 | Biosynthetic proline/alanine random coil polypeptides and their uses | |
HUE041350T2 | Biosynthetic proline/alanine random coil polypeptides and their uses | |
CN105477641A | Biosynthetic proline/alanine random coil polypeptides and their uses | |
KR20150092355A | Biological active proteins having increased in vivo and/or vitro stability |